Oragenics (OGEN) Stock Price, News & Analysis

Company Overview

Oragenics, Inc. is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures. In addition to its dental portfolio, Oragenics is advancing Ogi-04™, a therapeutic candidate for the prevention and treatment of oral mucositis, a common and painful side effect of cancer therapy. Oragenics’ research pipeline also includes earlier-stage programs aimed at broad-spectrum anti-infective applications.

Founded in 1996, Oragenics has built a foundation of proprietary peptide and gene-based platforms that support its drug discovery and development efforts. The company operates primarily in the United States but seeks to establish strategic collaborations to extend its reach into additional markets. Oragenics is listed on the New York Stock Exchange under the ticker symbol OGEN.

Oragenics is led by President and Chief Executive Officer Todd Korth, whose leadership and financial expertise have guided the company’s strategic direction and operational execution. The management team combines scientific experience with regulatory and commercial know-how to advance the company’s clinical programs toward potential commercialization.

Key Stats

• Today's Range: $1.28 to $1.40
• 50-Day Range: $1.03 to $1.42
• 52-Week Range: $1.01 to $18.90
• Volume: 165,475 shs
• Average Volume: 258,839 shs
• Market Capitalization: $5.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OGEN Stock Analysis - Frequently Asked Questions

How have OGEN shares performed this year?

Oragenics' stock was trading at $11.0790 on January 1st, 2025. Since then, OGEN stock has decreased by 88.3% and is now trading at $1.30.

How were Oragenics' earnings last quarter?

Oragenics, Inc. (NYSEAMERICAN:OGEN) posted its quarterly earnings data on Monday, August, 16th. The company reported ($54.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($72.00) by $18.00.

When did Oragenics' stock split?

Oragenics's stock reverse split before market open on Monday, January 23rd 2023.The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Oragenics?

Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Oragenics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oragenics investors own include Imunon (CLSN), Jaguar Animal Health (JAGX), Biocept (BIOC), OPKO Health (OPK), Sorrento Therapeutics (SRNE) and Amarin (AMRN).

Company Calendar

• Last Earnings: 8/16/2021
• Today: 10/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:OGEN
• Previous Symbol: NYSE:OGEN
• CIK: 1174940
• Web: www.oragenics.com
• Phone: 813-286-7900
• Fax: 813-286-7904
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($21.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.57 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -3,614.27%
• Return on Assets: -324.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.50
• Quick Ratio: 0.50

Sales & Book Value

• Annual Sales: $40 thousand
• Price / Sales: 134.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.51) per share
• Price / Book: -2.55

Miscellaneous

• Outstanding Shares: 4,130,000
• Free Float: 3,925,000
• Market Cap: $5.37 million
• Optionable: N/A
• Beta: 0.83